<?xml version="1.0" encoding="UTF-8"?>
<div id="ijms-18-02645-f001" orientation="portrait" position="float" class="fig" xmlns="http://www.w3.org/1999/xhtml">
 <span class="label">Figure 1</span>
 <div class="caption">
  <p>Omega-3 polyunsaturated fatty acid (PUFA) potential action in restoring eubiosis in gut microbiota. Dysbiosis of the 
   <span class="italic">Firmicutes/Bacteroidetes</span> ratio is associated with several conditions, such as weight gain and obesity [
   <a rid="B56-ijms-18-02645" ref-type="bibr" href="#B56-ijms-18-02645">56</a>], insulin resistance [
   <a rid="B56-ijms-18-02645" ref-type="bibr" href="#B56-ijms-18-02645">56</a>], high-fat diet [
   <a rid="B38-ijms-18-02645" ref-type="bibr" href="#B38-ijms-18-02645">38</a>,
   <a rid="B39-ijms-18-02645" ref-type="bibr" href="#B39-ijms-18-02645">39</a>], gut permeability [
   <a rid="B54-ijms-18-02645" ref-type="bibr" href="#B54-ijms-18-02645">54</a>], IBDs [
   <a rid="B21-ijms-18-02645" ref-type="bibr" href="#B21-ijms-18-02645">21</a>], and depression [
   <a rid="B88-ijms-18-02645" ref-type="bibr" href="#B88-ijms-18-02645">88</a>]. Similarly, a 
   <span class="italic">Bifidobacteria</span> decrease combined with a 
   <span class="italic">Enterobacteria</span> increase leads to the establishment of endotoxemia that causes a chronic low-grade inflammation associated with some pathological conditions, like insulin resistance [
   <a rid="B46-ijms-18-02645" ref-type="bibr" href="#B46-ijms-18-02645">46</a>], gut permeability [
   <a rid="B43-ijms-18-02645" ref-type="bibr" href="#B43-ijms-18-02645">43</a>,
   <a rid="B44-ijms-18-02645" ref-type="bibr" href="#B44-ijms-18-02645">44</a>], and depression [
   <a rid="B92-ijms-18-02645" ref-type="bibr" href="#B92-ijms-18-02645">92</a>]. Initial evidence shows that omega-3 PUFAs are able to reverse this condition by restoring the 
   <span class="italic">Firmicutes/Bacteroidetes</span> ratio, and increasing 
   <span class="italic">Lachnospiraceae</span> taxa [
   <a rid="B13-ijms-18-02645" ref-type="bibr" href="#B13-ijms-18-02645">13</a>,
   <a rid="B16-ijms-18-02645" ref-type="bibr" href="#B16-ijms-18-02645">16</a>,
   <a rid="B18-ijms-18-02645" ref-type="bibr" href="#B18-ijms-18-02645">18</a>,
   <a rid="B19-ijms-18-02645" ref-type="bibr" href="#B19-ijms-18-02645">19</a>,
   <a rid="B20-ijms-18-02645" ref-type="bibr" href="#B20-ijms-18-02645">20</a>], both associated with an increased production of the anti-inflammatory short-chain fatty acid (SCFA) butyrate [
   <a rid="B13-ijms-18-02645" ref-type="bibr" href="#B13-ijms-18-02645">13</a>,
   <a rid="B19-ijms-18-02645" ref-type="bibr" href="#B19-ijms-18-02645">19</a>,
   <a rid="B20-ijms-18-02645" ref-type="bibr" href="#B20-ijms-18-02645">20</a>]. Moreover, animal studies showed the ability of omega-3 PUFAs to increase lipopolysaccharide (LPS)-suppressing bacteria, 
   <span class="italic">Bifidobacteria</span>, and to decrease LPS-producing bacteria, 
   <span class="italic">Enterobacteria</span>, negating the endotoxemia phenomenon [
   <a rid="B52-ijms-18-02645" ref-type="bibr" href="#B52-ijms-18-02645">52</a>]. For all these actions, omega-3 PUFAs can be considered as prebiotics, able to restore gut eubiosis in some pathological conditions.
  </p>
 </div>
 <div xlink:href="ijms-18-02645-g001" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</div>
